

1/20

EV. 404052962 US
07-06-04

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

JUL 02 2004
O I P E JC10
PATENT & TRADEMARK OFFICE

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	10/657,932
		Filing Date	September 9, 2003
		First Named Inventor	Thomas Rogers
		Art Unit	1614
		Examiner Name	Unknown
Total Number of Pages in This Submission	248	Attorney Docket Number	3230/OA/US (6794-000096/DVA)

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i>
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Copies of Cited References; Return Receipt Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	Remarks
<input type="checkbox"/> Certified Copy of Priority Document(s)	Via Express Mail Label No. EV 404052962 US	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm or Individual name	James E. Davis, PTO Reg. No. 47,516 Harness, Dickey & Pierce, P.L.C
Signature	
Date	July 2, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	James E. Davis
Signature	
Date	July 2, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



EV 404052962 US

Attorney Docket No: 3230/0A/US
HDP Docket No: 6794-000096/US/DVA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Thomas Rogers et al.
Serial No: 10/657,932
Filed: September 9, 2003
For: Dihydrostilbene Alkanoic Acid Derivatives
Art Unit: 1614
Confirmation No. 1588
Examiner: TBA
Attorney Docket No: 3230/0A/US

July 2, 2004

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam/Sir:

In accordance with 37 CFR §1.97 and §1.98, and MPEP §609, and in compliance with the duty of disclosure set forth in 37 CFR §1.56 Applicants hereby submit the references cited on the attached Form PTO-1449 for consideration and entry in the above-referenced patent application.

Applicants submit this Information Disclosure Statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.56, but by listing such documents Applicants are not admitting that such documents are necessarily relevant or prior art. Applicants intend no representation that the listed documents represent the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104(a) and §1.106(b) and, in the course of such search, will review for relevance every document listed on the attached form even if not initialed.

References 1 - 6 cited in this Information Disclosure Statement were previously cited or submitted to the office and considered in parent application Serial No. 09/882,137. Therefore, copies of the references are not being provided in accordance with 37 CFR §1.98(d) and MPEP §609 Part III(2). However, Applicants will readily provide copies of such references if necessary.

Applicants believe that this Information Disclosure Statement is being submitted before the mailing of a first Office action on the merits and thus no fee is owed. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.


Respectfully submitted,



James E. Davis, PTO Reg. No. 47,516
Harness, Dickey & Pierce
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
(314) 726-7500 (tel)
(314) 726-7501 (fax)

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on July 2, 2004 with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.



Peggy Marie Leslie
Peggy Marie Leslie

JED/LMR



EV 404052962 US

FORM PTO-HDP-1449 (Based on Form PTO-1449)		ATTORNEY DOCKET NO.	SERIAL NO.
		3230/0A/US	10/657,932
		APPLICANT	
		Rogers et al.	
		FILING DATE	GROUP
		September 9, 2003	1614

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 1 of 3

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/Subclass	Translation Yes No
1.		WO 99/15508	04/01/99	PCT	C07D 239/02	
2.		WO 99/05107	02/04/99	PCT	C07D 211/72	
3.		WO 98/31359	07/23/98	PCT	A61K 31/18	
4.		WO 99/52896	10/21/99	PCT	C07D 401/12	
5.		WO 93/12796	07/08/93	PCT	A61K 31/415	
6.		EP 0 694 543	01/31/96	Europe	C07D 413/04	

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
7.		Berge et al., Pharmaceutical Salts, <i>J. Pharm. Sci.</i> , Vol. 66(1), pp. 1-19, January 1977
8.		Vu et al., Angiogenic Activity in Injured Rat Corneas as Assayed on the Chick Chorioallantoic Membrane, <i>Lab. Invest.</i> , Vol. 53(3), pp. 311-319, 1985
9.		Robertson et al., A Quantitative <i>In Vivo</i> Mouse Model Used to Assay Inhibitors of Tumor-induced Angiogenesis, <i>Cancer Res.</i> , Vol. 51, pp. 1339-1344, February 1991
10.		Ribatti et al., New Model for the Study of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane: The Gelatin Sponge/Chorioallatoic Membrane Assay, <i>J. Vasc. Res.</i> , Vol. 34, pp. 455-463, November-December 1997
11.		Carcellar et al., Synthesis and Structure-Activity Relationships of 1-Acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF Antagonists, <i>J. Med. Chem.</i> , Vol. 36, pp. 2984-2997, 1993
12.		Miller, W. H. et al., Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic, <i>J. Med. Chem.</i> , Vol. 43, pp. 22-26, 2000
13.		Pytela et al., Arginine-Glycine-Aspartic Acid Adhesion Receptors, <i>Methods in Enzymology</i> , Vol. 144, pp. 475-489, 1987
14.		Yatohgo et al., Novel Purification of Vitronectin for Human Plasma by Heparin Affinity Chromatography, <i>Cell Structure and Function</i> , Vol. 13, pp. 281-292, 1988

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 2 of 3

ATTORNEY DOCKET NO.	SERIAL NO.
3230/0A/US	10/657,932
APPLICANT	
Rogers et al.	
FILING DATE	GROUP
September 9, 2003	1614

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
15.		Charo et al., Inhibition of Fibrinogen Binding to GP IIb-IIIa by a GP IIIa Peptide, <i>J. Biol. Chem.</i> , Vol. 266(3), pp. 1415-1421, January 1991
16.		Niiya et al., Increased Surface Expression of the Membrane Glycoprotein IIb/IIIa Complex Induced by Platelet Activation. Relationship to the Binding of Fibrinogen and Platelet Aggregation, <i>Blood</i> , Vol. 70(2), pp. 475-483, August 1987
17.		Zucker, Platelet Aggregation Measured by the Photometric Method, <i>Methods in Enzymology</i> , Vol. 169, pp. 117-133, 1989
18.		Carron et al., A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy, <i>Cancer Res.</i> , Vol. 58(9), pp. 1930-1935, 1998
19.		Lark et al., Antagonism of the Osteoclast Vitronectin Receptor with an Orally Active Nonpeptide Inhibitor Prevents Cancellous Bone Loss in the Ovariectomized Rat, <i>J. Bone Miner. Res.</i> , Vol. 16(2), pp. 319-327, 2001
20.		Healy et al., Angiogenesis: a new theory for endometriosis, <i>Hum. Reproductive Update</i> , Vol. 4(5), pp. 736-740, 1998
21.		Cheresh., Structure, function and biological properties of integrin $\alpha_v\beta_3$ on human melanoma cells, <i>Cancer and Metastasis Rev.</i> , Vol. 10, pp. 3-10, 1991
22.		Friedlander, et al., Involvement of integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$ in ocular neovascular diseases, <i>Proc. Natl. Acad. Sci.</i> , Vol. 93, pp. 9764-9769, September 1996
23.		Badger et al., Disease-Modifying Activity of SB 273005, an Orally Active, Nonpeptide $\alpha_v\beta_3$ (Vitronectin Receptor) Antagonist, in Rat Adjuvant-Induced Arthritis, <i>Arthritis & Rheum.</i> , Vol. 44(1), pp. 128-137, January 2001
24.		Brown et al., Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis, <i>Cardiovascular Res.</i> , Vol. 28, pp. 1815-1820, 1994
25.		Seftor et al., Role of the $\alpha_v\beta_3$ integrin in human melanoma cell invasion, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, pp. 1557-1561, March 1992
26.		Montgomery et al., Integrin $\alpha_v\beta_3$ rescues melanoma cells from apoptosis in three-dimensional dermal collagen, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 8856-8860, September 1994
27.		Brooks et al., Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels, <i>Cell</i> , Vol. 79, pp. 1157-1164, December 1994

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
 (Use several sheets if necessary)

Sheet 3 of 3

ATTORNEY DOCKET NO.	SERIAL NO.
3230/0A/US	10/657,932
APPLICANT	
Rogers et al.	
FILING DATE	GROUP
September 9, 2003	1614

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
28.		Adamis et al., Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes with Proliferative Diabetic Retinopathy, <i>Amer. J. Ophthalm.</i> , Vol. 118, pp. 445-450, October 1994
29.		Peacock et al., Angiogenesis Inhibition Suppresses Collagen Arthritis, <i>J. Exp. Med.</i> , Vol. 175, pp. 1135-1138, April 1992
30.		Brooks et al., Requirement of Vascular Integrin $\alpha_v\beta_3$ for Angiogenesis, <i>Science</i> , Vol. 264, pp. 569-571
31.		Sato et al., Echistatin Is a Potent Inhibitor of Bone Resorption in Culture, <i>J. Cell. Biol.</i> , Vol. 111, pp. 1713-1723, October 1990
32.		Fisher et al., Inhibition of Osteoclastic Bone Resorption in Vivo by Echistatin, an "Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein, <i>Endocrinology</i> , Vol. 132(3), pp. 1411-1413, 1993
33.		Choi et al., Inhibition of neointimal hyperplasia by blocking $\alpha_v\beta_3$ integrin with a small peptide antagonist OpenGRGDSPCA, <i>J. Vasc. Surg.</i> , Vol. 19(1), pp. 125-134
34.		White, Integrins as virus receptors, <i>Current Biology</i> , Vol. 3(9), pp. 596-599, 1993
35.		Friedlander et al., Definition of Two Angiogenic Pathways by Distinct α_v Integrins, <i>Science</i> , Vol. 270, pp. 1500-1502, December 1995

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.